Synergistic efficacy of a novel combination therapy controls growth of Bcl-x L bountiful neuroblastoma cells by increasing differentiation and apoptosis

Cancer Biology and Therapy

Volumn 12, Issue 9, 2011, Pages 846-854

  Mohan, Nishant ^a   Banik, Naren L ^b   Ray, Swapan K ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

2,3 DCPE; 4 HPR; Apoptosis; Bcl x L; Combination therapy; Differentiation; Neuroblastoma

Indexed keywords

2 [[3 (2,3 DICHLOROPHENOXY)PROPYL]AMINO]ETHANOL; ANTINEOPLASTIC AGENT; BETA ACTIN; CASPASE 3; FENRETINIDE; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; METHYLENE BLUE; MYC PROTEIN; NEUROFILAMENT PROTEIN; NEURON SPECIFIC ENOLASE; NOTCH1 RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL STRUCTURE; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; GEL BLOT ANALYSIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; NEUROBLASTOMA CELL; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-X PROTEIN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; CHLOROBENZENES; DRUG SYNERGISM; ETHANOLAMINES; FENRETINIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEUROBLASTOMA;

EID: 80655140637     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.9.17715     Document Type: Article

References (32)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3:203-16; PMID:12612655; DOI:10.1038/nrc1014.
2. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369:2106- 20; PMID:17586306; DOI:10.1016/S0140-6736(07)60983-0.
3. L in cell death. Biochem Biophys Res Commun 2005; 333:336-43; PMID:15922292; DOI:10.1016/j.bbrc.2005.04.161.
4. L regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO J 1999; 18:632-43; PMID:9927423; DOI:10.1093/emboj/18.3.632.
5. L is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression. J Biol Chem 2010; 285:6904-12; PMID:20051518; DOI:10.1074/jbc.M109.038331.
6. L to induce apoptosis in colon cancer cells. J Biol Chem 2006; 281:16034-42; PMID:16608847; DOI:10.1074/jbc.M513587200.
7. L in cancer cells by a novel small molecule, 2[[3-(2,3-dichlorophenoxy) propyl]amino]ethanol. Cancer Res 2004; 64:1110-3; PMID:14871845; DOI:10.1158/0008-5472.CAN-03-2790.
8. L expression. Gynecol Oncol 2007; 105:373-84; PMID:17276501; DOI:10.1016/j.ygyno.2006.12.019.
9. Zhu H, Zhang L, Wu S. Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3-dichlorophenoxy) propyl] amino]ethanol in correlation with activation of ERK. Oncogene 2004; 23:4984-92; PMID:15122344; DOI:10.1038/sj.onc.1207645.
10. Smith MA, Anderson B. Where to next with retinoids for cancer therapy? Clin Cancer Res 2001; 7:2955-7; PMID:11595682.
11. Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev 2010; 62:1285-98; PMID:20654663; DOI:10.1016/j.addr.2010.07.003.
12. Karmakar S, Choudhury SR, Banik NL, Ray SK. Combination of N-(4-hydroxyphenyl) retinamide and genistein increased apoptosis in neuroblastoma SK-NBE2 and SH-SY5Y xenografts. Neuroscience 2009; 163:286-95; PMID:19540315; DOI:10.1016/j.neuroscience.2009.06.037.
13. Das A, Banik NL, Ray SK. Retinoids induce differentiation and downregulate telomerase activity and N-Myc to increase sensitivity to flavonoids for apoptosis in human malignant neuroblastoma SH-SY5Y cells. Int J Oncol 2009; 34:757-65; PMID:19212680.
14. Janardhanan R, Banik NL, Ray SK. N-Myc downregulation induced differentiation, early cell cycle exit and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53. Biochem Pharmacol 2009; 78:1105-14; PMID:19540207; DOI:10.1016/j.bcp.2009.06.009.
15. Llambi F, Green DR. Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev 2011; 21:12-20; PMID:21236661; DOI:10.1016/j.gde. 2010.12.001.
16. Mohan N, Karmakar S, Choudhury SR, Banik NL, Ray SK. Bcl-2 inhibitor HA14-1 and genistein together adeptly downregulated survival factors and activated cysteine proteases for apoptosis in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells. Brain Res 2009; 1283:155-66; PMID:19505441; DOI:10.1016/j.brainres.2009.05.097.
17. L is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995; 55:2576-82; PMID:7780971.
18. Sasaki A, Ogawa A, Nakazato Y, Ishida Y. Distribution of neurofilament protein and neuron-specific enolase in peripheral neuronal tumours. Virchows Arch A Pathol Anat Histopathol 1985; 407:33-41; PMID:3925624; DOI:10.1007/BF00701327.
19. Yeh YC, Wu CC, Wang YK, Tang MJ. DDR1 triggers epithelial cell differentiation by promoting cell adhesion through stabilization of e-cadherin. Mol Biol Cell 2011; 22:940-53; PMID:21289093; DOI:10.1091/mbc.E10-08-0678.
20. Weber GF, Bjerke MA, Desimone DW. Integrins and cadherins join forces to form adhesive networks. J Cell Sci 2011; 124:1183-93; PMID:21444749; DOI:10.1242/jcs.064618.
21. Chang HH, Lee H, Hu MK, Tsao PN. Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma. Clin Cancer Res 2010; 16:4411-20; PMID:20736329; DOI:10.1158/1078-0432.CCR-09-3360.
22. Grynfeld A, Axelson H. Induced neuroblastoma cell differentiation, associated with transient HES-1 activity and reduced HASH-1 expression, is inhibited by Notch1. Int J Cancer 2000; 88:401-10; PMID:11054669; DOI:10.1002/1097- 0215(20001101)88:3<401::AID-IJC12>3.0.CO;2-V.
23. Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene 2010; 29:1249-59; PMID:20101214; DOI:10.1038/onc.2009.512.
24. L retrotranslocates Bax from the mitochondria into the cytosol. Cell 2011; 145:104-16; PMID:21458670; DOI:10.1016/j.cell.2011.02.034.
25. L disrupts death-inducing signal complex formation in plasma membrane induced by hypoxia/reoxygenation. FASEB J 2004; 18:1826-33; PMID:15576486; DOI:10.1096/fj.04-2047com.
26. Leber B, Lin JL, Andrews DW. Still embedded togetherbinding to membranes regulates Bcl-2 protein interactions. Oncogene 2010; 29:5221-30; PMID:20639903; DOI:10.1038/onc.2010.283.
27. Labi V, Villunger A. PUMA-mediated tumor suppression: A tale of two stories. Cell Cycle 2010; 9:4269-75; PMID:20980816; DOI:10.4161/cc.9.21.13666.
28. Roberts CG, Millar EKA, O'Toole SA, McNei CM, Lehrbach GM, Pinese M, et al. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Oncogene 2011; 30:3186-97; PMID:21383694; DOI:10.1038/onc.2011.36.
29. L interaction trigger mitochondrial dysfunction after DNA damage. J Biol Chem 2010; 285:15016-26; PMID:20223826; DOI:10.1074/jbc.M109.086231.
30. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 2003; 17:1475-86; PMID:12783855; DOI:10.1101/gad.1093903.
31. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S, et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis: Caspase 3-resistent PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999; 274:22932-40; PMID:10438458; DOI:10.1074/jbc.274.33.22932.
32. Chou TC. Theoretical basis, experimental design and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-81; PMID:16968952; DOI:10.1124/pr.58.3.10.